Konica Minolta Raises $125,000 for Alzheimer’s Research
October 24, 2023 10:37 ET
|
Konica Minolta Business Solutions U.S.A., Inc.
Ramsey, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced the final fundraising results through its participation in the...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
June 01, 2023 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
April 25, 2023 08:00 ET
|
Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....
Vaccinex Announces $3.8 Million Private Placement
November 28, 2022 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Konica Minolta Raises $97,000 for Alzheimer’s Research
October 06, 2022 15:32 ET
|
Konica Minolta Business Solutions U.S.A., Inc.
Ramsey, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced the final fundraising results through its participation in the...
Help Dixie Belle Paint Raise Up to $15,000 for the Fight Against Alzheimer's.
September 06, 2022 15:00 ET
|
Dixie Belle Paint
PORT RICHEY, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Help Dixie Belle Paint raise up to $15,000 for the fight against Alzheimer's. Visit Dixie Belle on Facebook at Dixie Belle Paint Company and...
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
July 29, 2022 07:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
May 25, 2022 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports 2021 Financial Results and Provides Corporate Update
March 31, 2022 09:15 ET
|
Vaccinex, Inc.
Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC); Enrollment in Phase...
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
January 04, 2022 08:00 ET
|
Vaccinex, Inc.
Phase 1b segment evaluated safety and tolerability of the combination Paves the way to expand and accelerate enrollment in the Phase 2 segment of the study ROCHESTER, N.Y., Jan. 04, 2022 ...